Integrating redox biomarkers into patient stratification may also guide personalized use of GSH-responsive therapies
35 Key Corporate Highlights Advancing Novel Therapies for Diseases with High Unmet Needs Expected Upcoming Milestones Focus on diseases with well-defined mechanistic Phase 3 LUCIDITY topline data Q3 2026 Avexitide PBH Clinical anticipated in Q3 2026 rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data Commercial launch, if approved, 2027 Avexitide PBH Regulatory anticipated in 2027 First-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug AVEXITIDE designations Phase 1 LUMINA trial Cohort 1 (n=12) biomarker data to be presented at a 1H 2026 AMX0114 ALS Clinical Oral, fixed-dose combination of two medical meeting expected in 1H 2026 small molecules, sodium AMX0035 phenylbutyrate and taurursodiol PBH & Rare IND-enabling studies underway with an Antisense oligonucleotide designed to 2027 AMX0318 Preclinical target calpain-2, a protein involved in IND filing targeted for 2027 Diseases AMX0114 axonal degeneration & neurofilament biology with FDA Fast Track Designation Novel, long-acting GLP-1 AMX0318 receptor antagonist ALS=amyotrophic lateral sclerosis
The risks right around the time of surgery, so let's say within a month of surgery, are actually comparable to gallbladder surgery, believe it or not, which is kind of surprising, because it's often a bigger operation than that
Arrange imaging to help map the local extent and check for lymph node spread
